DENTSPLY SIRONA (NASDAQ:XRAY) Issues FY 2026 Earnings Guidance

Key Points

• DENTSPLY SIRONA’s FY 2026 outlook fell short of analyst expectations: It forecast EPS of $1.20–$1.30 versus a $1.47 consensus and revenue of $3.5 billion versus $3.6 billion.
• Analysts’ consensus rating was Hold, with a $12.62 average price target; three analysts rated the stock Buy, eight Hold and three Sell.
• XRAY shares traded down $0.59 to $10.06 during Thursday’s midday trading.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) updated its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 1.200-1.300 for the period, compared to the consensus earnings per share estimate of 1.470. The company issued revenue guidance of $3.5 billion, compared to the consensus revenue estimate of $3.6 billion.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Barrington Research lowered their price target on shares of DENTSPLY SIRONA from $15.00 to $13.00 and set an "outperform" rating on the stock in a research report on Monday, October 26th. Mizuho lowered their target price on shares of DENTSPLY SIRONA from $14.00 to $12.00 and set a "neutral" rating for the company in a research note on Thursday, October 22nd. Barclays raised their price target on DENTSPLY SIRONA from $9.00 to $11.00 and gave the stock an "underweight" rating in a research note on Monday, August 24th. Leerink Partners lowered their price objective on shares of DENTSPLY SIRONA from $14.00 to $10.00 and set a "market perform" rating for the company in a research note on Wednesday, October 14th. Finally, BMO Capital Markets cut their price objective on DENTSPLY SIRONA from $13.00 to $10.00 and set a "market perform" rating on the stock in a research report on Thursday, September 17th. Three equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $12.62.

DENTSPLY SIRONA Price Performance

Shares of XRAY stock traded down $0.59 during midday trading on Thursday, reaching $10.06. 5,030,676 shares of the company were exchanged, compared to its average volume of 4,890,916. The company's 50 day moving average price is $9.65 and its two-hundred day moving average price is $11.30. The company has a market cap of $2.01 billion, a P/E ratio of -3.66, a PEG ratio of 1.25 and a beta of 0.87. DENTSPLY SIRONA has a 12 month low of $8.32 and a 12 month high of $14.76. The company has a debt-to-equity ratio of 1.48, a quick ratio of 1.07 and a current ratio of 1.63.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.35 by $0.17. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.84%. The business had revenue of $898.00 million during the quarter, compared to analysts' expectations of $889.93 million. During the same period last year, the firm posted $0.52 earnings per share. The business's revenue was down 4.1% on a year-over-year basis. On average, sell-side analysts expect that DENTSPLY SIRONA will post 1.39 earnings per share for the current year.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA is a global manufacturer of professional dental products and technologies. The company serves dentists, dental specialists, dental laboratories and other oral health professionals with solutions used in preventive, restorative, prosthetic, endodontic and implant dentistry.

Its portfolio includes dental equipment, imaging and treatment systems, CAD/CAM technology, consumable dental materials, orthodontic products, endodontic instruments and solutions, dental implants, prosthetic components and laboratory products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.